JP2016513724A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513724A5
JP2016513724A5 JP2016502709A JP2016502709A JP2016513724A5 JP 2016513724 A5 JP2016513724 A5 JP 2016513724A5 JP 2016502709 A JP2016502709 A JP 2016502709A JP 2016502709 A JP2016502709 A JP 2016502709A JP 2016513724 A5 JP2016513724 A5 JP 2016513724A5
Authority
JP
Japan
Prior art keywords
matrix
particle size
dosage form
drug
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502709A
Other languages
English (en)
Japanese (ja)
Other versions
JP6463333B2 (ja
JP2016513724A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/028125 external-priority patent/WO2014143935A1/en
Publication of JP2016513724A publication Critical patent/JP2016513724A/ja
Publication of JP2016513724A5 publication Critical patent/JP2016513724A5/ja
Application granted granted Critical
Publication of JP6463333B2 publication Critical patent/JP6463333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502709A 2013-03-15 2014-03-14 オキシカルバゼピンの急速分散性の剤形 Active JP6463333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791726P 2013-03-15 2013-03-15
US61/791,726 2013-03-15
PCT/US2014/028125 WO2014143935A1 (en) 2013-03-15 2014-03-14 Rapidly dispersible dosage form of oxcarbazepine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018172088A Division JP2019006812A (ja) 2013-03-15 2018-09-14 オキシカルバゼピンの急速分散性の剤形

Publications (3)

Publication Number Publication Date
JP2016513724A JP2016513724A (ja) 2016-05-16
JP2016513724A5 true JP2016513724A5 (enExample) 2017-04-06
JP6463333B2 JP6463333B2 (ja) 2019-01-30

Family

ID=51537567

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502709A Active JP6463333B2 (ja) 2013-03-15 2014-03-14 オキシカルバゼピンの急速分散性の剤形
JP2018172088A Abandoned JP2019006812A (ja) 2013-03-15 2018-09-14 オキシカルバゼピンの急速分散性の剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018172088A Abandoned JP2019006812A (ja) 2013-03-15 2018-09-14 オキシカルバゼピンの急速分散性の剤形

Country Status (10)

Country Link
US (4) US9314429B2 (enExample)
EP (1) EP2968354B1 (enExample)
JP (2) JP6463333B2 (enExample)
CN (1) CN105050604B (enExample)
AU (2) AU2014228063B2 (enExample)
CA (1) CA2906107C (enExample)
ES (1) ES2761265T3 (enExample)
HK (1) HK1213472A1 (enExample)
MX (1) MX364381B (enExample)
WO (1) WO2014143935A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431141B1 (en) 2013-03-15 2021-12-08 Aprecia Pharmaceuticals LLC Three-dimensional printing method
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
WO2015168463A1 (en) * 2014-05-02 2015-11-05 University Of Louisville Research Foundation, Inc. Methods for fabricating dental restorations
WO2016192680A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
CN105770899A (zh) * 2016-03-07 2016-07-20 北京诺康达医药科技有限公司 一种大剂量药物的速释制剂及其制备方法
EP3429556A1 (en) * 2016-03-18 2019-01-23 Grünenthal GmbH Floating pharmaceutical dosage form
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
GB201612853D0 (en) 2016-07-25 2016-09-07 Univ Central Lancashire Solid dosage form production
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
US10703549B2 (en) 2017-06-30 2020-07-07 The Procter And Gamble Company Water soluble containers and methods of making them
EP3701038B1 (en) * 2017-10-26 2024-10-09 Merck Patent GmbH Methods for performing cell culture
WO2019137200A1 (en) 2018-01-09 2019-07-18 Triastek, Inc. Oral drug dosage forms comprising a fixed-dose of an adhd non-stimulant and an adhd stimulant
CN112867482B (zh) 2018-10-15 2023-04-25 阿普雷奇亚制药有限责任公司 在包装内形成剂型的方法和系统
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
JPWO2020149200A1 (ja) 2019-01-18 2021-11-25 株式会社Ihi スラストフォイル軸受
EP3789015A1 (en) 2019-09-05 2021-03-10 Universität Innsbruck Fast consolidating compounds
ES2828509B2 (es) 2019-11-26 2022-03-09 Fund Idonial Composicion para la impresion 3d de farmacos semisolidos
JP2023522035A (ja) * 2020-04-15 2023-05-26 アプレシア・ファーマスーティカルズ・エルエルシー 多成分パッケージ化投薬形態および方法
MX2022016117A (es) 2020-06-26 2023-04-05 Aprecia Pharmaceuticals LLC Tabletas rapidamente orodispersables que tienen una cavidad interior.
WO2024038000A1 (en) * 2022-08-18 2024-02-22 Merck Patent Gmbh Process for the manufacture of a solid pharmaceutical administration form
WO2024108082A1 (en) 2022-11-18 2024-05-23 Aprecia Pharmaceuticals LLC Orodispersive dosage forms containing droxidopa
FR3162625A1 (fr) * 2024-05-30 2025-12-05 Mb Therapeutics Formulation pharmaceutique imprimable par extrusion, cartouche d’impression renfermant une telle formulation et procédé de préparation d’un médicament la mettant en œuvre

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5631023A (en) 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
ATE421318T1 (de) 1997-02-20 2009-02-15 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
EP1194153B1 (en) 1999-07-09 2004-05-06 Ortho-McNeil Pharmaceutical, Inc. Taste masked pharmaceutical liquid formulations
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
CA2408956C (en) * 2000-05-18 2011-07-12 Therics, Inc. Method and form of a drug delivery device,such as encapsulating a toxic core within a non-toxic region in an oral dosage form
MXPA03008057A (es) 2001-03-05 2004-10-15 Johnson & Johnson Composiciones farmaceuticas con sabor oculto.
KR20040002976A (ko) * 2001-05-18 2004-01-07 랜박시 래보러터리스 리미티드 옥스카르바제핀 제형
WO2003041690A2 (en) * 2001-10-29 2003-05-22 Therics, Inc. Three-dimensional suspension printing of dosage forms
WO2004022037A1 (en) 2002-09-04 2004-03-18 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
WO2004052345A1 (en) 2002-12-11 2004-06-24 Ranbaxy Laboratories Limited Coating composition for taste masking coating and methods for their application and use
CA2524806C (en) 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
FR2858556B1 (fr) 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
BRPI0413881A (pt) 2003-08-28 2006-10-24 Sandoz Ag composição farmacêutica compreendendo anticonvulsivante com revestimento de mascaramento de gosto
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20060182796A1 (en) 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
JP2008540346A (ja) * 2006-01-31 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド オキシカルバゼピンの医薬製剤及びその調製方法
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
US20070178164A1 (en) 2006-01-31 2007-08-02 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
EP2010499A4 (en) * 2006-04-21 2012-07-18 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION OF OXCARBAZEPINE PARTICULATE FROM 15 TO 30 MICRONS IN AVERAGE
WO2008141751A2 (en) * 2007-05-23 2008-11-27 Ratiopharm Gmbh Pharmaceutical compositions comprising oxcarbazepine
EP2397161B1 (en) 2009-02-12 2019-09-25 Fuji Chemical Industry Co., Ltd. Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same
US20100285130A1 (en) 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20120076858A1 (en) 2009-06-04 2012-03-29 Basf Se Orally Disintegrating Dosage Forms Containing Taste-Masked Active Ingredients
EP2467126A1 (en) 2009-08-19 2012-06-27 Bayer Pharma Aktiengesellschaft Drug delivery systems (wafer) for pediatric use
AR079862A1 (es) 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
US9381154B2 (en) * 2011-06-09 2016-07-05 Xerox Corporation Direct inkjet fabrication of drug delivery devices

Similar Documents

Publication Publication Date Title
JP2016513724A5 (enExample)
WO2014143935A4 (en) Rapidly dispersible dosage form of oxcarbazepine
JP5911927B2 (ja) 併用治療のための錠剤
JP2016514686A5 (enExample)
KR20190107712A (ko) 특정 위장 부위에서의 제어 방출의 투여 형태
JP2016514680A5 (enExample)
JP2012144577A5 (enExample)
KR102046248B1 (ko) 다공성 위체류층을 포함하는 서방성 제제 및 이의 제조방법
WO2012164578A1 (en) Compositions and methods for preparing immediate release formulations of nilotinib
SI2729130T1 (en) Combined formulations of darunavir
HRP20240045T1 (hr) Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta
HRP20190550T1 (hr) Formule i metode proizvodnje formulacija za upotrebu u pražnjenju debelog crijeva
Ganesh et al. In vitro evaluation of the effect of combination of hydrophilic and hydrophobic polymers on controlled release zidovudine matrix tablets
JP5775463B2 (ja) 溶出安定性製剤
Aslam et al. Techniques and polymers used to design Gastroretentive drug delivery systems–a review
JP5347092B2 (ja) アンドログラフィス抽出物製剤
RU2662562C2 (ru) Композиция в форме таблеток, содержащая гидрохлорид цинакалцета
JP2017520619A5 (enExample)
Purushothaman et al. Formulation development and Evaluation of immediate and sustained release Bilayer Tablets Containing Amitriptyline HCl and Pregabalin for the treatment of Neuropathic Pain
CN108289849A (zh) 莫沙必利与雷贝拉唑的复合制剂
Khemariya et al. Preparation and in-vitro evaluation of sustained-release matrix tablets of Diltiazem
WO2005082329A2 (en) Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
EP3496719A1 (en) A multi-class anti-retroviral composition
JP2018530538A5 (enExample)
JP5910311B2 (ja) 医薬錠剤およびその製造方法